Pharming Outpaces Estimates as Stoneridge Pivots to Multi-Year Guidance
Pharming Group N.V. exceeded revenue expectations and provided a robust 2026 outlook, signaling strong adoption of its rare disease portfolio. Conversely, Stoneridge Inc. missed top-line targets but attempted to anchor investor confidence with a new two-year strategic forecast through 2027.